- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07942701
Generating Medical Discharge Report Drafts Via Artificial Intelligence (Letter)
A key process in intensive care is the creation of transfer reports. These summarize the essential aspects of the treatment to date and ensure that information is passed on to the next treatment team in a structured manner. They contain, among other things, diagnoses, relevant examination results, and therapeutic measures that have been carried out. The aim of a transfer report is to document the patient's medical history and the course of treatment to date in a concise and complete manner. Incomplete transfer reports can lead to repeated examinations, which can potentially delay further therapy and endanger the patient, as well as incurring additional costs.
In this context, a complete transfer report ensures continuity of treatment and contributes significantly to patient safety.
Transfer reports are created from a synthesis of a large number of documents. In addition to medical facts from tables and free-text summaries, physicians also draw on their experience to pass on relevant information to future treatment teams in the synthesis of detailed documentation. This process naturally requires a great deal of time and concentration in patients receiving intensive care.
Artificial intelligence methods, such as large language models (LLMs), could be used to learn how to create transfer reports and formulate drafts.
LLMs can convert unstructured free text into a structured form, thereby facilitating the report creation process. This would make it possible to generate a pre-formulated draft that doctors could then review and supplement.
At present, transfer reports are created by physicians with considerable effort and time. The methods currently available for automating report generation are limited to text modules that largely bundle data sources deterministically. Some of these methods are already commercially available, but they are not capable of creating individual reports beyond form letters.
The automatic analysis of unstructured text data falls within a subfield of AI known as natural language processing (NLP), which also includes language models (LLMs) such as ChatGPT and Gemini, which have been popular since 2022. A major milestone was reached with the development of the Transformer architecture in 2017, which, in addition to the availability of enormous amounts of training data (e.g., Wikipedia, news articles, or books), forms the basis for many groundbreaking language models. The effectiveness of these LLMs is limited for specific domains such as medicine, as the training data often lacks relevant characteristics such as complex terminology or writing styles. Adapting these models for clinical use to improve patient care, research, and medical education is a highly topical field of research. The most relevant foreign-language models include BioBERT, Meditron, and Med-PaLM. As of July 2024, there is only limited research on the development of German-language models, e.g., medBERT, BioGottBERT, and a few models that are not publicly available.
The sole use of LLMs is problematic due to non-reproducible results, lack of transparency, and bias in the models. Knowledge graphs (KGs) are used in medicine to represent and analyze complex information structures. The creation of a "robust digital patient twin" would be improved by the use of LLMs and KGs. This would allow the state of health to be assessed based on all digitally available clinical information (both structured and, in this project, now also unstructured). Recent studies confirm that adapted LLMs in the English language domain can produce summaries that are equivalent to or better than those produced by human experts, and that these are often difficult to distinguish from reports written by humans.
The legal framework for this results from a complex interaction of legal provisions from data protection law (with regard to health data), artificial intelligence law (AI Act), medical law (in particular hospital law), (medical) product law, medical professional law, and other relevant professional groups (e.g., nursing and pharmacy), as well as relevant civil and criminal law standards of care. In addition, there are fundamental rights requirements based on the ECHR and the EU Charter of Fundamental Rights. Data protection issues relating to the use of health data, in particular for research with AI systems, and professional law issues in connection with automated aggregation and presentation have already been examined in detail (as part of the SMARAGD project, FFG 872575).
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Thomas Tschoellitsch, MD
- Phone Number: 78132 +435768083
- Email: thomas.tschoellitsch@jku.at
Study Contact Backup
- Name: Jens Meier, MD
- Phone Number: 2158 +435768083
- Email: jens.meier@jku.at
Study Locations
-
-
Upper Austria
-
Linz, Upper Austria, Austria, 4020
- Recruiting
- Johannes Kepler University, Kepler University Hospital
-
Contact:
- Thomas Tschoellitsch, MD
- Phone Number: 78132 +435768083
- Email: thomas.tschoellitsch@jku.at
-
Contact:
- Jens Meier, MD
- Phone Number: 2158 +435768083
- Email: jens.meier@jku.at
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients treated in intensive care units.
Description
Inclusion Criteria:
- Treated in intensive care units between 2008-11-01 to 2025-05-31 at the study center.
Exclusion Criteria:
- Refusal to participate in scientific studies.
Study Plan
How is the study designed?
Design Details
- Observational Models: OTHER
- Time Perspectives: RETROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Discharge Report Drafts
Time Frame: 2008-11-01 to 2025-05-31
|
Quality of Discharge Report Drafts evaluated based on technical parameters and assessed by human experts. Factual correctness: Accurate reproduction of e.g. diagnoses, medication versus hallucinations using Entity Matching Score (Percentage of correctly reproduced entities compared with the source data) and Hallucination Rate (Proportion of unverifiable statements). Completeness: All relevant information is included using checklist compliance (proportion of required fields covered) and Recall against Reference Texts (comparison with physician-written letters, e.g. using ROUGE-L). Clinical Validity: Recommendations must be evidence-based and consistent with clinical guidelines using guideline-adherence (e.g. rule-based systems or LLM-based assessments). Structure is assessed with template compliance using NLP-based section recognition. Data Protection: Degree of Anonymization using NER models. Comprehensibility: Clear, precise language without ambiguities using Readability Assessment. |
2008-11-01 to 2025-05-31
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Traceability
Time Frame: 2008-11-01 to 2025-05-31
|
The data sources used to create text passages should be visualized so that the steps performed by the AI can be explained and traced. Traceability should also be evaluated by human experts. |
2008-11-01 to 2025-05-31
|
|
Degree of Necessary Adjustments
Time Frame: 2008-11-01 to 2025-05-31
|
The degree of necessary adjustments to drafts should be evaluated proportionally as a percentage of the total text and based on the type of adjustments made by human experts (e.g., spelling errors, content corrections, additions). |
2008-11-01 to 2025-05-31
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas Tschoellitsch, MD, Johannes Kepler University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- MEDI-DOK Letter
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.